EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog‐mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis

Sikai Wu, Jiheng Niu, Xiaowei Chen, Jinfei Li, Quanying Tang, Zhenlin Yang, Shugeng Gao

Clinical and Translational Medicine · 2026-04 · 16 (4)

DOI: 10.1002/ctm2.70670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 20.04.2026. Verfasst von Sikai Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Adenocarcinoma of Lung, Lung Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding, National Key R&D Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kirsten rat sarcoma viral oncogene homolog (KRAS)‐mutant lung adenocarcinoma (LUAD) typically demonstrates limited response to neoadjuvant immunotherapy (NIT). Elucidating the immune determinants that differentiate responders from non‐responders was critical for optimizing immunotherapy strategies. This study aimed to characterize the tumour microenvironment features of KRAS‐mutant LUAD following neoadjuvant programmed death protein 1 (PD‐1) inhibitor therapy by integrating clinical outcomes with single‐cell RNA sequencing (scRNA‐seq).

Methods

A total of 143 patients with resectable LUAD were consecutively enrolled in this study, including 106 cases in the KRAS‐wildtype cohort and 37 cases in the KRAS‐mutant cohort. We systematically compared the pathological response rates, survival outcomes and recurrence patterns between the two cohorts. We performed scRNA‐seq on tumour specimens from 234 real‐world patients with non‐small cell lung cancer. From this cohort, 48 LUAD cases were identified and stratified by KRAS mutation status (13 KRAS‐mutant and 35 KRAS‐wildtype patients). Cellular compositions, transcriptional features and intercellular communication networks were analysed.

Results

Clinical analysis revealed that the KRAS‐mutant group exhibited significantly poorer pathological responses ( p = .032) and inferior long‐term survival compared to the KRAS‐wildtype group. We identified an immunosuppressive tumour necrosis factor receptor superfamily member 4 (TNFRSF4)‐expressing regulatory T‐cell (CD4T_Treg_TNFRSF4) subset enriched in non‐responders, whereas responders showed increased frequencies of T helper 1 cells (Th1 cells) and a previously unrecognized exhausted‐like B‐cell state (Bex). Bex cells displayed impaired metabolic activity yet retained antigen presentation potential and showed extensive cellular interactions with Th1 cells, suggesting a supportive role in Th1‐mediated antitumour immunity.

Conclusion

KRAS‐mutant patients exhibited significantly poorer pathological responses, and KRAS‐mutant status may independently predict survival outcomes after NIT in LUAD patients. Additionally, our study unveiled the cellular and molecular architecture underlying differential responses to NIT in KRAS‐mutant LUAD, emphasizing the opposing roles of immunosuppressive Tregs and synergistic Bex–Th1 networks. Highlights KRAS‐mutant LUAD patients exhibit inferior pathological responses and survival after neoadjuvant immunotherapy compared to KRAS‐wildtype patients. A CD4T_Treg_TNFRSF4 subset is enriched in non‐responders, defining an immunosuppressive microenvironment. Responders are characterized by a synergistic network between Th1 cells and a novel exhausted‐like B‐cell (Bex) state. The balance between immunosuppressive Tregs and the Th1/Bex axis determines therapeutic efficacy in KRAS‐mutant LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyAdenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)ImmunotherapyHumansMaleFemaleMutationTumor MicroenvironmentMiddle AgedAgedTreatment Effect Heterogeneity

Stichwörter der Autor:innen

KRAS‐mutant lung adenocarcinomaneoadjuvant immunotherapysingle‐cell RNA sequencingtumour microenvironment

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • School of Basic Medical Sciences, Tsinghua University, Beijing, China.
  • Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Förderung

  • National High Level Hospital Clinical Research Funding
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Central Health Research Key Projects
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • Beijing Natural Science Foundation
  • Young Elite Scientists Sponsorship Program by CAST
  • National Key Research and Development Program of China

Zitieren

APA

Wu, S., Niu, J., Chen, X., Li, J., Tang, Q., Yang, Z., & Gao, S. (2026). The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog‐mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis. Clinical and Translational Medicine, 16(4). https://doi.org/10.1002/ctm2.70670

Vancouver

Wu S, Niu J, Chen X, Li J, Tang Q, Yang Z, et al. The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog‐mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis. Clinical and Translational Medicine. 2026;16(4). doi:10.1002/ctm2.70670

BibTeX
@article{Wu2026,
  author = {Wu, Sikai and Niu, Jiheng and Chen, Xiaowei and Li, Jinfei and Tang, Quanying and Yang, Zhenlin and Gao, Shugeng},
  title = {The landscape of responses to neoadjuvant immunotherapy in resectable Kirsten rat sarcoma viral oncogene homolog‐mutant lung adenocarcinoma: Clinical heterogeneity and correlative immunologic analysis},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  volume = {16},
  number = {4},
  doi = {10.1002/ctm2.70670}
}
Kostenlos starten →